工程化抗原呈递细胞及其用途

By expressing extracellular vesicle internalization receptor (EVIR) on antigen-presenting cells, the problems of low efficiency and high cost of existing cancer vaccines are solved, enabling personalized, broad T-cell responses and cancer treatment effects.

CN108602873BActive Publication Date: 2026-07-17ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Filing Date
2017-02-01
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing cancer vaccines are not very efficient at inducing T-cell responses specific to a variety of known and unknown tumor-associated antigens, and their ex vivo operation is labor-intensive and expensive, making them unsuitable for most patients.

Method used

We designed and expressed an extracellular vesicle internalization receptor (EVIR) on antigen-presenting cells (APCs) to enable them to efficiently take up and internalize cancer cell-derived extracellular vesicles, thereby enhancing the presentation of various cancer-associated antigens and T cell activation.

Benefits of technology

It enables personalized and broad T-cell responses, improves the therapeutic effect of cancer vaccines, reduces operational complexity and cost, and is suitable for most patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0001751009350000361
    Figure BDA0001751009350000361
  • Figure BDA0001751009350000371
    Figure BDA0001751009350000371
  • Figure BDA0001751009350000481
    Figure BDA0001751009350000481
Patent Text Reader

Abstract

本发明涉及工程化的胞外囊泡内化受体，其具有增强抗原呈递细胞对肿瘤相关抗原的T细胞的摄取、加工和呈递的能力。它还涉及表达所述受体的载体或抗原呈递细胞，其组合物及其用于预防和 / 或治疗癌症的用途。
Need to check novelty before this filing date? Find Prior Art